RxDoctor Payments DataLook up a doctor →

Brian Campbell Jimenez, MD

Hematology & Oncology · Pine Bluff, ARNPI 1548668916

Payments from drug & device makers

$7,102in general payments, 2019–2025

Across 370 payments — averaging $19.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$947
  • Pfizer$448
  • EMD Serono, Inc.$361
  • Lilly USA, LLC$350
  • E.r. Squibb & Sons, L.L.C.$278
  • Johnson & Johnson$246
  • plus $4K from 46 others

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis59$947
Pfizer26$448
EMD Serono, Inc.17$361
Lilly USA, LLC10$350
E.r. Squibb & Sons, L.L.C.17$278
Johnson & Johnson7$246
Ipsen Biopharmaceuticals, Inc14$236
Bristol Myers Squibb13$230
Amgen11$230
Seagen Inc.9$229
Sanofi9$203
GSK11$188
Genentech USA, Inc.9$173
Daiichi Sankyo Inc.9$167
Gilead(2 entities)10$157
Eisai Inc.8$155
AstraZeneca7$152
Merck9$152
Beigene USA, Inc.8$148
Rigel Pharmaceuticals, Inc.10$145
AbbVie8$136
Astellas Pharma US Inc7$122
Array Biopharma Inc6$115
Regeneron Healthcare Solutions, Inc.5$114
Boehringer Ingelheim4$113
Pharmacyclics LLC, An Abbvie Company7$107
Puma Biotechnology, Inc.6$97
Takeda Pharmaceuticals U.S.A., Inc.5$96
Blueprint Medicines Corporation1$93
AVEO Pharmaceuticals, Inc.5$86
Sobi, Inc4$85
Incyte Corporation5$83
Pharmaessentia USA Corporation4$66
Exelixis Inc.3$62
Genentech, Inc.1$50
Karyopharm Therapeutics Inc.3$46
Adaptive Biotechnologies Corporation2$45
Sanofi-aventis U.S. LLC1$42
Recordati_rare_diseases_inc.2$40
Azurity Pharmaceuticals, Inc.2$37
Mirati Therapeutics, Inc.2$35
G1 Therapeutics, Inc.2$31
Beone Medicines USA, Inc.2$30
Emmaus Medical, Inc.1$30
Bayer2$29
Geron Corporation1$20
Dendreon Pharmaceuticals LLC1$19
Tersera Therapeutics LLC1$17
Sun Pharmaceutical Industries Inc.1$16
Taiho Oncology, Inc.1$15
Alnylam Pharmaceuticals Inc.1$14
Pharmacosmos Therapeutics Inc.1$14

How this compares

$7,102 in reported general payments places this provider in the 45th percentile of 92 hematology & oncology providers in Arkansas.

See all hematology & oncology providers in Arkansas →

Medicare billing

Part B allowed, 2024
$67,907
Medicare patients
281
Services billed
666

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Pine Bluff

See the full list for Arkansas →

Where these figures come from

Is this you, or does something look wrong? →